CompletedPHASE2, PHASE3NCT05433350
Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric Patients
Studying African trypanosomiasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Drugs for Neglected Diseases
- Principal Investigator
- Victor Kande Betu Ku Mesu, DrMinistry of Public Health, Hygiene and Prevention, Kinshasa
- Intervention
- Acoziborole(drug)
- Enrollment
- 35 enrolled
- Eligibility
- 1-14 years · All sexes
- Timeline
- 2022 – 2026
Study locations (6)
- General Hospital of Bandundu, Bandundu Province, Bandundu, Democratic Republic of the Congo
- CDTC Katanda, Katanda, East Kasai, Democratic Republic of the Congo
- Hôpital Général de Dipumba, Mbuji-Mayi, East Kasai, Democratic Republic of the Congo
- HGR Bagata, Bagata, Kwilu, Democratic Republic of the Congo
- Hospital of Masi-Manimba, Masi-Manimba, Kwilu, Democratic Republic of the Congo
- General Referral Hospital of Dubreka, Dubréka, Guinea
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05433350 on ClinicalTrials.govOther trials for African trypanosomiasis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07106385The Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) on Improving Sleep Quality in Adults Without Serious Mental IllnessThe University of Hong Kong
- ACTIVE NOT RECRUITINGNCT04565769Cognitive Function in Melanoma Patients Treated With Adjuvant Immune Checkpoint InhibitorsAarhus University Hospital
- RECRUITINGNCT01778504Studying Childhood-onset Behavioral, Psychiatric, and Developmental DisordersNational Institute of Mental Health (NIMH)